相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Editorial Material
Infectious Diseases
David Hui
LANCET INFECTIOUS DISEASES
(2023)
Article
Geriatrics & Gerontology
Pedro P. España et al.
Journal of the American Medical Directors Association
(2023)
Article
Geriatrics & Gerontology
Silvia Pierobon et al.
Summary: This study assessed the impact of SARS-CoV-2 infection among nursing home residents in the Veneto Region, finding that they had a higher risk of COVID-19 infection, hospitalization, and death compared to the general older population. However, from late December 2020 to May 2021, 95% of NH residents and healthcare professionals in Italy received at least one vaccine dose, resulting in decreased risk ratios for all outcomes in NH.
Article
Biochemistry & Molecular Biology
Alison Tarke et al.
Summary: T cell responses induced by different vaccine platforms cross-recognize early SARS-CoV-2 variants, while memory B cells and neutralizing antibodies show significant decreases. The majority of memory T cell responses are preserved against variants, with lower recognition of Omicron by memory B cells.
Article
Medicine, General & Internal
Emma K. Accorsi et al.
Summary: Assessing the performance of COVID-19 vaccines against the Omicron variant is crucial for public health guidance. This study found that receiving three doses of mRNA COVID-19 vaccine was associated with a lower likelihood of symptomatic SARS-CoV-2 infection compared to being unvaccinated or receiving two doses. These findings suggest that three doses of mRNA vaccine provide protection against both Omicron and Delta variants, though the protection against Omicron may be slightly lower.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Letter
Medicine, General & Internal
Mary Wu et al.
Article
Medicine, General & Internal
Sue Ann Costa Clemens et al.
Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.
Article
Biochemistry & Molecular Biology
Nick Andrews et al.
Summary: This study examined the relative and absolute effectiveness of mRNA booster vaccination against COVID-19. The results showed that the booster dose of BNT162b2 or mRNA-1273 had a relative effectiveness ranging from 85% to 95% against symptomatic disease, and an absolute effectiveness ranging from 94% to 97%. For hospitalization or death, the absolute effectiveness of the BNT162b2 booster ranged from 97% to 99% in all age groups. The study provides real-world evidence of significantly increased protection from the booster vaccine dose against mild and severe disease.
Article
Medicine, General & Internal
Victoria Hall et al.
Summary: This study investigated the duration and effectiveness of immunity among healthcare workers in the United Kingdom. It found that two doses of the BNT162b2 vaccine provided high short-term protection against SARS-CoV-2 infection, but this protection significantly decreased after six months. However, infection-acquired immunity boosted by vaccination remained high, even more than one year after infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Khitam Muhsen et al.
Summary: During a surge of Covid-19 cases in Israel, a rapid deployment of BNT162b2 booster injections in long-term care facilities over a 3-week period in July resulted in a 71% decrease in infection rates and an 80% decrease in hospitalization rates, while general population infection rates were increasing.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Nick Andrews et al.
Summary: A study conducted in England showed that vaccines against SARS-CoV-2 provide high protection against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. However, the effectiveness of the vaccines decreases over time, especially in individuals aged 65 and older and those with underlying risk factors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ariel Hammerman et al.
Summary: This retrospective cohort study in Israel found that receiving at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection among patients who had recovered from Covid-19. Vaccine effectiveness was similar for one dose and two doses.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Rolando Pajon et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Francois Helle et al.
Summary: This study investigated the humoral response in nursing home patients who received the BioNTech vaccine and found that those with prior infection had a stronger antibody response. Although all patients developed an immune response to the vaccine, the intensity appeared to depend on previous infection status.
Review
Immunology
Sandro M. Hirabara et al.
Summary: This review addresses key issues regarding SARS-CoV-2 variants, including the characteristics of variants with mutations in the S gene, evasion of neutralizing antibodies, potential risks of new pandemic waves, and prospects for further research and actions to prevent or reduce the impact of new variants during the current COVID-19 pandemic.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Jill M. Ferdinands et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Immunology
Adeel A. Butt et al.
Summary: While the relative vaccine effectiveness of a booster dose of the COVID-19 mRNA vaccine in preventing infection against the Omicron variant is low, it is substantial in preventing hospitalization and high in preventing the most severe/critical disease.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Geriatrics & Gerontology
Helene Jeulin et al.
Summary: The duration of IgG(S) response to the mRNA BNT162b2 vaccine in nursing home residents with or without history of SARS-CoV-2 infection was studied. Results showed that residents with previous COVID-19 infection had a longer duration of robust protection compared to those without infection. The third dose of the vaccine induced a stronger IgG(S) response in residents without infection, providing prolonged protection against severe forms of COVID-19.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2022)
Editorial Material
Medicine, General & Internal
Halane Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Article
Infectious Diseases
Peter Nordstrom et al.
Summary: This retrospective cohort study investigated the effectiveness of COVID-19 vaccination in individuals who had previously been infected with SARS-CoV-2. The study found that natural immunity provided protection against SARS-CoV-2 infection and COVID-19 hospitalization for up to 20 months. Vaccination further reduced the risk of reinfection and hospitalization for up to 9 months, although the differences in absolute numbers, especially in hospitalizations, were small.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Roanne Keeton et al.
Summary: Despite reduced neutralizing antibody activity, T cell responses induced by vaccination or infection can cross-recognize the Omicron variant and provide protection.
Editorial Material
Medicine, General & Internal
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Article
Immunology
Toon Braeye et al.
Summary: The study re-assessed vaccine effectiveness against transmission of infection and found that mRNA vaccines had higher effectiveness compared to viral vector vaccines, while the Delta variant led to increased transmission odds and reduced vaccine efficacy, especially in older age groups.
Letter
Medicine, General & Internal
Jessica P. Ridgway et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Medicine, General & Internal
Fiona P. Havers et al.
Summary: Understanding the factors that contribute to hospitalization in vaccinated individuals is crucial for combating COVID-19. This study found that unvaccinated adults were more likely to be hospitalized compared to vaccinated adults, with the lowest hospitalization rates observed in those who had received a booster dose.
JAMA INTERNAL MEDICINE
(2022)
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: This study used data from the Israeli Ministry of Health database to compare the rate of infection with the time since immunity-confering events. The results showed that the protection against reinfection decreased over time for individuals who had previously been infected or vaccinated, but it was still higher than the protection conferred after the same time had elapsed since the second dose of vaccine among those who were previously uninfected. A single dose of vaccine after infection reinforced protection against reinfection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Medicine, General & Internal
Daniel R. Feikin et al.
Summary: This study systematically reviewed the duration of protection provided by COVID-19 vaccines against various clinical outcomes. The findings indicate that the effectiveness or efficacy of the vaccines decreased from 1 to 6 months after full vaccination, but remained high against severe disease. Evaluating the effectiveness or efficacy of vaccines beyond 6 months is crucial for updating vaccine policies.
Article
Biochemistry & Molecular Biology
Anthony T. DiPiazza et al.
Summary: SARS-CoV-2, transmitted via respiratory particles, has caused the COVID-19 pandemic with severe economic consequences. Cellular immunity plays a crucial role in limiting disease severity, emphasizing the importance of understanding the functional capacity and role of SARS-CoV-2-specific T cells for natural infection and vaccination responses.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Letter
Medicine, General & Internal
Diana Zhong et al.
Summary: This study compares the durability of antibodies in individuals who received mRNA SARS-CoV-2 vaccine with prior infection and those without infection.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Laith J. Abu-Raddad et al.
Summary: This study aimed to assess the protection against breakthrough infection with SARS-CoV-2 after mRNA vaccination, comparing individuals with and without prior infection. The findings showed that individuals with prior SARS-CoV-2 infection had a significantly lower risk for breakthrough infection, indicating a potential benefit of natural immunity in vaccine protection.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Marcello Morciano et al.
Summary: By August 7, 2020, there were 29,542 (95% CI 25,176 to 33,908) excess deaths in all care homes in England. Excess deaths accounted for 6.5% (95% CI 5.5 to 7.4%) of all care home beds, with a higher rate in nursing homes (8.4%) compared to residential homes (4.6%). 64.7% (95% CI 56.4 to 76.0%) of excess deaths were confirmed/suspected COVID-19 cases. The odds of experiencing COVID-19 attributable deaths were higher in homes providing nursing services, with older residents and/or dementia patients, larger homes, and belonging to a large provider/brand, but not significantly associated with for-profit status.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cell Biology
Allison J. Greaney et al.
Summary: Vaccine-elicited antibodies have more focused neutralizing activity on the RBD of the SARS-CoV-2 spike protein, while infection-elicited antibodies have broader binding across epitopes; hence, single RBD mutations have less impact on neutralization by vaccine sera.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Medicine, General & Internal
Carmen Cabezas et al.
Summary: Vaccination showed a significant reduction of 80-91% in SARS-CoV-2 infection across all three cohorts, with greater reductions in hospital admissions and mortality among nursing home residents.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Public, Environmental & Occupational Health
Wesley H. Self et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
